Browsing Tag
GlaxoSmithKline
31 posts
Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?
Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market.
Is pharma nationalism reshaping global R&D? What GSK, Eli Lilly, and AstraZeneca are signaling to the world
GSK, Eli Lilly and AstraZeneca are reshaping global pharma strategy with massive U.S. investments—find out what this means for R&D, supply chains, and policy.
Why GSK is investing $30bn in the U.S. now—and what it means for global pharma manufacturing
GSK to invest $30B in U.S. R&D and manufacturing amid trade policy shifts—find out how this shapes global pharma supply chains and investor sentiment.
Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to…
Pfizer to offload 540 million shares in shocking Haleon sale—What does this mean for the healthcare giant?
In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately…
Glenmark Pharmaceuticals gets FDA final approval for Compazine generic
Glenmark Pharmaceuticals has bagged final approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg from the…
Strides Pharma gets FDA approval for Ibuprofen oral suspension
Strides Pharma Science Limited said that its stepdown fully-owned subsidiary — Strides Pharma Global Pte. Limited, Singapore, has…
GSK to acquire vaccine developer Affinivax in deal worth up to $3.3bn
GlaxoSmithKline (GSK) has agreed to acquire Affinivax, a Boston-based clinical-stage vaccine developer, in a deal worth up to…
GSK to acquire US biopharma company Sierra Oncology for $1.9bn
GlaxoSmithKline (GSK) has agreed to acquire Sierra Oncology, a California-based biopharma company, in a deal worth around $1.9…
GlaxoSmithKline to transfer rights to Iodex and Ostocalcium for Rs 16.5bn
GlaxoSmithKline Pharmaceuticals Limited said that it will transfer its rights pertaining to the Iodex pain relief and Ostocalcium…